{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000911216","name":"PALATIN TECHNOLOGIES INC","summary":". Our Business Overview Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatins strategy is to develop products and then form marketing collaborations with industry leaders to maximize product commercial potential. The MCR ...","people":[],"products":[{"name":"PL7737","type":"platform","description":"Oral MC4R selective small molecule agonist in IND-enabling stage for obesity treatment."},{"name":"Long-acting Peptide MC4R Agonist","type":"platform","description":"Novel MC4R selective long-acting peptide agonist in lead compound selection for obesity."},{"name":"Bremelanotide + Tirzepatide","type":"service","description":"Co-administration Phase 2 study for obesity; positive topline data reported Q1 2025."},{"name":"PL9643","type":"platform","description":"Topical MC1R/MC5R peptide agonist ophthalmic solution for dry eye disease; completed Phase 3 MELODY-1 with positive results."},{"name":"PL8177","type":"platform","description":"Oral polymer-encapsulated MC1R agonist peptide for inflammatory bowel disease including ulcerative colitis; Phase 2 topline data reported Q1 2025."},{"name":"Vyleesi (bremelanotide)","type":"platform","description":"FDA-approved MCR agonist auto-injector for premenopausal women with HSDD; sold to Cosette in December 2023."}],"partnerships":[{"partner_name":"Cosette","partnership_type":"licensing","description":"Acquired Vyleesi (bremelanotide) from Palatin in December 2023, including future milestone payments.","start_date":null},{"partner_name":"Boehringer Ingelheim International GmbH","partnership_type":"licensing","description":"Acquired certain Palatin patent applications for melanocortin receptor-targeted peptides for retinal diseases and glaucoma in August 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"0f988647418438a297e082844df95a8726f2beb02509c81aaa3953ac702d2e0f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bb7ce51e9db6c246f555823f4eb118e9bd9db65fb97d7ad5b7f1fc06fc826a57","parent":"e91d785336667ba22cc1e3a0a48b72a2f70941b2110f3b031904f1aef4aef2ab","source":"0001654954-25-011030, 0001493152-26-044572","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":194,"hourly_limit":500,"remaining":306,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}